findmyKOL

James Eichelberger, MD

Basic profile

University of Rochester Medical Center

ORCIDNone on fileNPI
RegionRochester, NY · NortheastSpecialtyCardiovascular DiseaseFocusCardiology
Last active 2023findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2018Online presenceNot yet checkedPayments2021 onwardNIH funding2000–2002Why? →

James Eichelberger is a Cardiology physician affiliated with University of Rochester Medical Center. OpenAlex indexes 27 publications with 272 citations (h-index 6).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
27publications

Distinct works indexed by OpenAlex.

272citations

Total citations across indexed works.

6h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 2000–2002

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

601 Elmwood Ave
Rochester, NY 146420002

Telephone

585-341-7700

Registry record last updated 30 Jun 2023.

View the NPPES registry record

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    84.2%
    Beta blocker21.5%
    Metoprolol Succinate51%Metoprolol Tartrate23%Carvedilol15%Atenolol8%Bisoprolol Fumarate2%Sotalol1%
    Part D<11 patients
    Statin16.8%
    Atorvastatin Calcium65%Rosuvastatin Calcium27%Pravastatin Sodium5%Simvastatin4%
    Part D<11 patients

    + 14 more classes in this area

  • Blood & clotting

    14.2%
    Factor Xa inhibitor9.2%
    Eliquis78%Xarelto22%
    Part D72 patients
    P2Y12 inhibitor2.9%
    Clopidogrel100%
    Part D31 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    1%
    SGLT2 inhibitor0.6%
    Jardiance100%
    Part D<11 patients
    Proton pump inhibitor0.4%
    Pantoprazole Sodium100%
    Part D<11 patients
Where care is delivered (Part B)34.1% facility · 65.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 20002002 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”